August 29, 2026
Research Use Only. This article is educational and describes published laboratory and clinical research. It is not medical advice, and nothing here describes or endorses human use of any research compound.
Retatrutide has become one of the most-discussed molecules in metabolic research, and much of that discussion outpaces what the peer-reviewed record actually says. This article stays close to the primary literature: what the compound is at the receptor level, what the published trials measured, and what the data does and does not establish. It is written for a research audience evaluating the compound in laboratory contexts.
Retatrutide is a synthetic peptide characterized in the literature as a triple agonist — it activates three receptors at once: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor (Jastreboff AM et al., New England Journal of Medicine 2023;389:514–526). That third arm, glucagon-receptor agonism, is what distinguishes it in research discussions from dual GIP/GLP-1 agonists, because glucagon-receptor activity has been studied for its role in energy expenditure pathways.
The compound remains investigational and is not approved by the FDA for any use (Eli Lilly, via PR Newswire, December 11, 2025). In a research setting it is handled strictly as a research-use-only material.
The Phase 2 findings were published in the New England Journal of Medicine in 2023. In that 48-week trial, the highest-dose research cohort showed a mean body-weight reduction of up to 24.2% at 48 weeks; the sponsor separately reported a 17.5% mean reduction at the 24-week mark (Jastreboff AM et al., NEJM 2023;389:514–526; Eli Lilly release, June 26, 2023).
Those figures are frequently quoted without their context, so two points matter for anyone reading the research: the results were dose-dependent, and they were measured under a controlled clinical-trial protocol — not a claim that transfers to any other setting.
The Phase 3 TRIUMPH program has since begun reporting. In TRIUMPH-4 (trial identifier NCT05869903), a 68-week trial that randomized 445 participants, the reported mean weight change was −26.4% at the 9 mg dose and −28.7% at the 12 mg dose, versus −2.1% for placebo (Eli Lilly, via PR Newswire, December 11, 2025).
The same release reported the adverse-event profile, which is an essential part of reading any trial honestly. The most common adverse events for retatrutide (9 mg / 12 mg respectively) were nausea (38.1% / 43.2%), diarrhea (34.7% / 33.1%), constipation (21.8% / 25.0%), and vomiting (20.4% / 20.9%). Discontinuation due to adverse events was 12.2% at 9 mg and 18.2% at 12 mg, versus 4.0% for placebo (Eli Lilly, via PR Newswire, December 11, 2025). A complete picture of a research compound includes its tolerability signals, not only its efficacy headline.
The published record describes what happened under specific trial protocols. It does not establish outcomes outside those protocols, and because retatrutide is still moving through Phase 3, its long-term profile is still being characterized. Anyone evaluating the compound in a research context should treat the figures above as trial-specific measurements, cite the primary sources directly, and avoid extrapolating beyond them.
Research peptides like retatrutide are supplied as lyophilized material for laboratory research and require appropriate reconstitution and cold-chain handling. For the mechanics of handling shipped research peptides, see our companion guide, Peptide Reconstitution 101: A Research Handling Guide.
If you evaluate compounds for research, the two things worth demanding from any supplier are transparency on identity and third-party analytical testing. Our Retatrutide research listing includes its analytical handling details, and our catalog is organized around that same standard.
Explore the Retatrutide research listing →
All products referenced are sold for research use only (RUO) and are not for human or veterinary consumption, diagnostic, or therapeutic use. Retatrutide is an investigational compound that is not approved by the FDA for any use. This article summarizes published research for educational purposes only and makes no health, treatment, or performance claims.
